{"disease":{"id":"maintenance-of-normal-sinus-rhythm-delay-in-af-afl-recurrence","name":"maintenance of normal sinus rhythm delay in af afl recurrence"},"drugs":{"marketed":[{"drug_id":"tikosyn","indication_name":"Maintenance of Normal Sinus Rhythm (Delay in AF/AFl Recurrence)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tikosyn","generic_name":"Dofetilide","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"IKr potassium channel (rapid component of delayed rectifier potassium current)","drug_class":"Vaughan Williams Class III antiarrhythmic","quality_score":10,"revenue":null,"mechanism":"Blocks cardiac potassium channel IKr to prolong repolarization and delay arrhythmia recurrence."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"tikosyn","guideline_body":"FDA label","recommendation":"TIKOSYN is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm.","line_of_therapy":"2L","evidence_grade":"B","guideline_year":null}],"source":"Drug Landscape verified database"}